Gemcitabine,nab-paclitaxel,RenovoCath
RenovoRx
[]
positive data from the tiger-pac study interim analysis demonstrating renovogem patients may experience a 60% survival benefit &amp; a 65% side effects reduction vs. systemic chemotherapy will be presented at #aacr23 today, april 17 in poster #ct084. $rnxt 
RenovoRx is fighting cancer through the localized treatment of difficult-to-treat tumors via its proprietary RenovoTAMP™ therapy platform.  Nasdaq: $RNXT